medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 5

<< Back Next >>

Ann Hepatol 2015; 14 (5)

Increase of drug use and genotype 3 in HCV-infected patients from Central West and Northeast Mexico

Muñoz-Espinosa LE, Trujillo-Trujillo ME, Martínez-Macías RF, Panduro A, Rivas-Estilla AM, Fierro NA, Silvera-Linares AL, Torres-Valadez R, Cordero-Pérez P, González-Aldaco K, Chen-López CY, José-Abrego A, Zuñiga-Noriega JR, Gutiérrez-Ruiz MC, Roman S

Language: English
References: 50
Page: 642-651
PDF size: 135.13 Kb.


ABSTRACT

Background. The evolving pattern of HCV genotypes (GTs) and risk factors (RFs) in HCV-infected patients in Mexico is poorly understood. This study aimed to access the temporal trend of HCV GTs and RFs in HCV patients from two care centers. Material and methods. Chronic HCV patients [177 and 153 patients from the Northeast (NE) and Central West (CW) regions, respectively] were selected. Baseline features were demographics, date of birth (DOB), blood transfusion before 1992 (BTb1992), RFs, sexual promiscuity (SP), dental procedure (DP), injection drug use (IDU), viral load (VL), GTs, cirrhosis status and antiviral therapy (AT). Data were analyzed by Chi-square test for trends, unpaired T-test, and logistic regression.Results. HCV GT distribution was: GT1, 67%; GT2, 16%; GT3, 12% and GT4, 1%. RFs were BTb1992, 56%; surgeries, 56%; tattooing, 18% and IDU, 16%. GT1a mostly prevailed in CW than NE patients. GT1b, surgeries, BTb1992 and cirrhosis were more prevalent in older patients (p ‹ 0.05); GT3, male gender IDU, SP, and tattooing showed an upward trend as younger were the patients in both regions (p ‹ 0.05), contrariwise to the prevalence of GT1b. BTb1992 and surgeries were seen in elder women; BTb1992 was an independent RF for GT1. Age ≥ 50 years old, GT1 and exposure to AT (p ‹ 0.05) were associated with cirrhosis. Conclusion. GT1a prevalence in CW Mexico remained stable, whereas GT3 increased and GT1b decreased in younger patients in both regions, along with associated RFs. Further regional molecular epidemiology and RF analyses are required in order to avoid the dissemination of new cases of HCV infection.


REFERENCES

  1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infec 2011; 17: 107-15.

  2. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91-133.

  3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-27.

  4. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. The epidemic behavior of the Hepatitis C virus. Science 2001; 292: 2323-5.

  5. Klenerman P, Gupta PK. Hepatitis C virus: current concepts and future challenges. Q J Med 2012; 105: 29-32.

  6. Cochrane A, Searle B, Hardie A, Robertson R, Delahooke T, Cameron S, Tedder RS, et al. A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis 2002; 186: 1212-21.

  7. Panduro A, Roman S, Khan A, Tanaka Y, Kurbanov F, Martinez- Lopez E, Campollo O, et al. Molecular epidemiology of hepatitis C virus genotypes in West Mexico. Virus Res 2010; 151: 19-25.

  8. Alvarado-Mora MV, Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Antivir Ther 2013; 18: 429-33.

  9. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42.

  10. Pujol FH, Roman S, Panduro A, Navas MC, Lampe E. Hepatocellular carcinoma in Latin America. In: Isabelle Chemin (ed.). Hepatocellular Carcinoma: A Global Challenge. New York: Nova Sciences Publishers, Inc.; 2012, p. 55-68.

  11. Kershenobich D, Razavi HA, Sánchez-Avila JF, Bessone F, Coelho HS, Dagher L, Gonçales FL, et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31: 18-29.

  12. Méndez-Sánchez N, Gutiérrez-Grobe Y, Kobashi-Margáin RA. Epidemiology of HCV infection in Latin America. Ann Hepatol 2010; 9(Suppl.): 27-9.

  13. Panduro A, Escobedo Melendez G, Fierro NA, Ruiz Madrigal B, Zepeda-Carrillo EA, Roman S. Epidemiología de las hepatitis virales en México. Sal Pub Mex 2011; 53(Suppl. 1): S37-S45.

  14. Escobedo G, Fierro NA, Roman S, Maldonado M, Zepeda-Carrillo E, Panduro A. Prevalence of hepatitis A, B and C serological markers in children from western Mexico. Ann Hepatol 2012; 11: 194-201.

  15. Chiquete E, Panduro A. Low prevalence of anti-hepatitis C virus antibodies in Mexico: A systematic review. Intervirology 2007; 50: 1-8.

  16. Santos-López G, Sosa-Jurado F, Vallejo-Ruiz V, Meléndez- Mena D, Reyes-Leyva J. Prevalence of hepatitis C virus in the Mexican population: a systematic review. J Infect 2008; 56: 281-90.

  17. Sosa-Jurado F, Santos-López G, Guzmán-Flores B, Ruiz- Conde JI, Meléndez-Mena D, Vargas-Maldonado MT, Martínez- Laguna Y, et al. Hepatitis C virus infection in blood donors from the state of Puebla, Mexico. Virol J 2010; 7: 18.

  18. Campollo O, Roman S, Panduro A, Hernandez G, Diaz-Barriga L, Balanzario MC, Cunnigham JK. Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug Alcohol Depend 2012; 123: 269-72.

  19. Calderón GM, González-Velázquez F, González-Bonilla CR, Novelo-Garza B, Terrazas JJ, Martínez-Rodríguez ML, Cortés- Márquez SR, et al. Prevalence and risk factors of hepatitis C virus, hepatitis B virus, and human immunodeficiency virus in multiply transfused recipients in Mexico. Transfusion 2009; 49: 2200-07.

  20. Rivas-Estilla AM, Sanchez LV, Matsui O, Campollo O, Armendariz- Borunda J, Segura-Ortega JE, Panduro A. Identification of hepatitis C virus (HCV) genotypes in infected patients from the west of Mexico. Hepatol Res 1998; 12: 121-30.

  21. Rivas-Estilla AM, Cordero-Pérez P, Trujillo-Murillo K del C, Ramos-Jiménez J, Chen-López C, Garza-Rodríguez M de L, Ramírez-Gutiérrez A, et al. Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. Ann Hepatol 2008; 7: 144-7.

  22. Dehesa-Violante M, Bosques-Padilla F, Kershenobich-Stalnikowitz D; Mexican Study Group of Pegasys. Prevalence of hepatitis C virus genotypes in Mexican patients. Rev Gastroenterol Mex 2007; 72: 344-8.

  23. Jimenez-Mendez R, Uribe-Salas F, Lopez-Guillen P, Cisneros- Garza L, Castañeda-Hernandez G. Distribution of HCV genotypes and HCV RNA viral load in different regions of Mexico. Ann Hepatol 2010; 9: 33-9.

  24. Sánchez-Avila JF, González E, Vázquez V, Suárez S, Uribe M. Geographical distribution of HCV genotypes in Mexico. Ann Hepatol 2007; 6: 156-60.

  25. Valdespino JL, Conde-González CJ, Olaiz-Fernández G, Palma O, Kershenobich D, Sepúlveda J. Seroprevalencia de la hepatitis C en adultos de México: ¿un problema de salud pública emergente? Sal Pub Mex 2007; 49(Suppl. 3): S395- S403.

  26. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36: S65-S73.

  27. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.

  28. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8.

  29. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-73.

  30. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  31. Johnson RA, Wichern DW (eds.). Applied Multivariate Statistical Analysis. New Jersey: Prentice Hall; 2002, p. 767.

  32. Brenn T, Arnesen E. Selecting risk factors: a comparison of discriminant analysis, logistic regression and Cox’s regression model using data from the Tromsø Heart Study. Stat Med 1985; 4: 413-23.

  33. Vera de León L, Juárez Navarro JA, Díaz Gómez M, Méndez Navarro J, Chirino Sprung RA, Dehesa Violante M, Casillas Davila L, et al. Epidemiologic and situational panorama of hepatitis C in Mexico. Rev Gastroenterol Mex 2005; 70: 25-32.

  34. García-Montalvo BM, Galguera-Colorado PL. Distribution of hepatitis C virus genotypes, risk factors and liver disease in patients from Yucatan, Mexico. Ann Hepatol 2008; 7: 345-9.

  35. Rivas-Estilla AM, Ramírez-Valles E, Martinez-Hernández R, Charles-Niño C, Ramírez-Camacho E, Rositas-Noriega F, Garza-Rodriguez ML, et al. Hepatitis C virus infection among HIV-1 infected individuals from northern Mexico. Hepatol Res 2007; 37: 311-6.

  36. Bruggmann P, Berg T, Øvrehus AL, Moreno C, Brandão Mello CE, Roudot-Thoraval F, Marinho RT, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21: 5-33.

  37. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, Dalgard O, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31: 30-60.

  38. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62.

  39. Dias PT, Hahn JA, Delwart E, Edlin BR, Martin J, Lum P, Evans J, et al. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco, California. BMC Infect Dis 2011; 11: 208.

  40. Sievert W, Altraif I, Razavi HA, Abdo A, Ahmed EA, Alomair A, Amarapurkar D, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31: 61-80.

  41. Ahmad W, Ijaz B, Javed FT, Jahan S, Shahid I, Khan FM, Hassan S. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. World J Gasterol 2010; 16: 4321-8.

  42. Benítez-Arvizu G, Cortez-Gómez R, Novelo-Garza BA, Malagón-Martínez A, Guerra-Márquez A, Alvarado-Maldonado M del C, Rodríguez-Bartolo M, et al. Prevalence of hepatitis C virus in the blood bank at Centro Médico Nacional La Raza. Rev Med Inst Mex Seguro Soc 2006; 44: 227-33.

  43. Bucardo J, Brouwer KC, Magis-Rodríguez C, Ramos R, Fraga M, Perez SG, Patterson TL, et al. Historical trends in the production and consumption of illicit drugs in Mexico: implications for the prevention of blood borne infections. Drug Alcohol Depend 2005; 79: 281-93.

  44. Chiquete E, Sánchez LV, Panduro A. Routes of infection and clinical outcome of Mexican women reactive to anti-hepatitis C virus antibodies. Hepatol Res 2006; 36: 100-06.

  45. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011; 31: 1090-101.

  46. Borges G, Medina-Mora ME, Breslau J, Aguilar-Gaxiola S. The effect of migration to the United States on substance use disorders among returned Mexican migrants and families of migrants. Am J Public Health 2007; 97: 1847-51.

  47. Brouwer KC, Lozada R, Cornelius WA, Firestone Cruz M, Magis-Rodríguez C, Zúñiga de Nuncio ML, Strathdee SA. Deportation along the U.S.-Mexico border: its relation to drug use patterns and accessing care. J Immigr Minor Health 2009; 11: 1-6.

  48. White EF, Garfein RS, Brouwer KC, Lozada R, Ramos R, Firestone- Cruz M, Pérez SG, et al. Prevalence of hepatitis C virus and HIV infection among injection drug users in two Mexican cities bordering the U.S. Sal Pub Mex 2007; 49: 165-72.

  49. Méndez JC, Dagher L. Limited access to protease inhibitors therapy for chronic HCV in the region: YES. Current Hepatitis Reports 2013; 12: 280-7.

  50. Dore G, Ward J, Thursz M. Hepatitis C disease burden and strategies to manage the burden. J Viral Hepat 2014; 21(Suppl.): 1-4.




2020     |     www.medigraphic.com